Risk factors
Aurinia Pharmaceuticals (AUPH) risk factors
Item 1A of every Aurinia Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors30 risks2 new5 dropped9 reworded
U.S. pharmaceutical trade-policy investigation creates new exposure for Canadian operations importing Swiss-manufactured products.
Filed Feb 26, 2026 - FY2024 10-K risk factors33 risks
Aurinia is heavily dependent on the commercial success of its sole approved product, LUPKYNIS, and the clinical development of AUR200. Restructurings in 2024 significantly reduced headcount by 25% and 45% to cut operating costs.
Filed Feb 27, 2025